Tag: NOX

Noxopharm investigational new drug IND FDA Veyonda ASX NOX approval

Noxopharm receives FDA investigational new drug approval for Veyonda

Oncology drug development company Noxopharm (ASX: NOX) has received FDA investigational new drug (IND) approval for using its Veyonda in combination with doxorubicin to...
Noxopharm LuPIN interim trial data Veyonda end-stage prostate cancer treatment

Noxopharm reports positive interim clinical trial results for cancer drug Veyonda

Biotech company Noxopharm’s (ASX: NOX) came out of a trading halt this morning with positive interim results from its LuPIN phase I/II clinical trial into...
Nyrada ASX IPO

Noxopharm’s US biotech subsidiary Nyrada IPO successfully raises $8.5m

Australian biotech Noxopharm’s (ASX: NOX) US spin-off Nyrada Inc (ASX: NYR) experienced strong demand in its initial public offering and will now make its ASX...
Noxopharm clinical data treatment late-stage prostate cancer ASX NOX

Noxopharm clinical data shows potential for major new treatment of late-stage prostate cancer

Biotech drug developer Noxopharm (ASX: NOX) has reported positive end-of-study results from its DARRT-1 phase 1b trial treating men with late-stage prostate cancer. In an...
Noxopharm ASX NOX anti-cancer effect DARRT prostate brain

Noxopharm confirms durable anti-cancer effect from lead drug Veyonda

Anti-cancer drug developer Noxopharm (ASX: NOX) has set the stage to present its highly-anticipated clinical data to the Clinical Oncology Society of Australia by publishing...
Noxopharm ASX NOX LuPIN positive interim results prostate cancer drug study radioactive therapy

Noxopharm releases positive interim results from prostate cancer drug study using radioactive therapy

Australian biotech drug developer Noxopharm (ASX: NOX) has reported positive interim results from its LuPIN study involving the Veyonda drug developed for men with...
Noxopharm ASX NOX interim clinical benefits treating prostate cancer Veyonda

Noxopharm reports interim ‘clinical benefits’ in treating prostate cancer with Veyonda

Noxopharm (ASX: NOX) has reported interim clinical benefits from an ongoing 24-week trial combining its Veyonda drug with radiotherapy in treating prostate cancer patients. Previously...
Noxopharm ASX NOX Nyrada treatment autoimmune disease inhibit IRAK4

Noxopharm and Nyrada discover ‘major development’ for treatment of autoimmune diseases

Biotech drug developer Noxopharm (ASX: NOX) has made an important drug discovery which could potentially help the company develop a treatment that mitigates the effects of...
Noxopharm ASX NOX brain cancer radiation drug idronoxil

Pre-clinical data suggests Noxopharm’s anti-cancer drug can boost radiation effect on paediatric brain cancer

Pre-clinical data has confirmed Noxopharm’s (ASX: NOX) experimental idronoxil anti-cancer drug can boost the killing effect of radiation when treating paediatric brain cancer cells. Noxopharm...
Noxopharm ASX NOX tumour treatment reverse late-stage metastatic cancer

Noxopharm hopeful tumour treatment can help reverse late-stage metastatic cancer

Chief executive Dr Graham Kelly has shared his hope drug developer Noxopharm’s (ASX: NOX) NOX66 therapeutic could be a major advance in the treatment...
Noxopharm ASX NOX toxic assumptions chemotherapy CEP-1 clinical study

Noxopharm looks to remove toxic assumptions from chemotherapy

Biotech drug developer Noxopharm (ASX: NOX) has presented its most-recent clinical data from its groundbreaking CEP-1 clinical study, at the ESMO International Congress on...
Noxopharm NOX66 St Vincent's Hospital cancer study

Noxopharm to commence NOX66 cancer study at St Vincent’s Hospital

Noxopharm (ASX: NOX) has announced the involvement of its experimental drug, NOX66, in a clinical study looking at the ability of a pioneering form...

RECENT POSTS

STOCK SUMMARY

FOLLOW US

HOT TOPICS

TRENDING POSTS